FluQuadri Inactivated Quadrivalent Influenza Vaccine (Split Virion), Influenza virus haemagglutinin 60mcg, 0.5mL suspension for injection (213963)

ARTG ID 213963

ARTG Name

FluQuadri Inactivated Quadrivalent Influenza Vaccine (Split Virion), Influenza virus haemagglutinin 60mcg, 0.5mL suspension for injection

Product name

FluQuadri Inactivated Quadrivalent Influenza Vaccine (Split Virion), Influenza virus haemagglutinin 60mcg, 0.5mL suspension for injection - 2025 season

ARTG Date

2 December 2014

Registration Type

Medicine

Therapeutic good type

Medicine

Ingredients

Influenza virus haemagglutinin

Licence category

Licence status

Summary

Download PDF

Product information

Download PDF

Consumer medicine information

Download PDF

Related information

FluQuadri Inactivated Quadrivalent Influenza Vaccine (Split Virion), Influenza virus haemagglutinin 60 mcg, 0.5 mL suspension for injection, Sanofi Aventis Australia Pty Ltd, CON-262

24 May 2018

Section 14 consent

Consent to while noncompliant with standards.
FluQuadri Inactivated Quadrivalent Influenza Vaccine (Split Virion), Influenza virus haemagglutinin 60 mcg, 0.5 mL suspension for injection, Sanofi Aventis Australia Pty Ltd, CON-268

4 June 2018

Section 14 consent

Consent to while noncompliant with standards.
FluQuadri Inactivated Quadrivalent Influenza Vaccine (Split Virion), Influenza virus haemagglutinin 60 mcg, 0.5 mL suspension for injection, Sanofi Aventis Australia Pty Ltd, CON-274

19 June 2018

Section 14 consent

Consent to while noncompliant with standards.
FluQuadri Inactivated Quadrivalent Influenza Vaccine (Split Virion), Influenza virus haemagglutinin 60 mcg, 0.5 mL suspension for injection, Sanofi Aventis Australia Pty Ltd, CON-333

6 June 2019

Section 14 consent

Consent to while noncompliant with standards.
FluQuadri Inactivated Quadrivalent Influenza Vaccine (Split Virion), Influenza virus haemagglutinin 60 mcg, 0.5 mL suspension for injection, Sanofi Aventis Australia Pty Ltd, CON-334

24 June 2019

Section 14 consent

Consent to while noncompliant with standards.
FluQuadri Inactivated Quadrivalent Influenza Vaccine (Split Virion), Influenza virus haemagglutinin 60mcg, 0.5mL suspension for injection, Sanofi Aventis Australia Pty Ltd, CON-331

28 May 2019

Section 14 consent

Consent to while noncompliant with standards.
FluQuadri Inactivated Quadrivalent Influenza Vaccine (Split Virion), Influenza virus haemagglutinin 60mcg, 0.5mL suspension for injection, Sanofi Aventis Australia Pty Ltd, CON-408

4 May 2020

Section 14 consent

Consent to while noncompliant with standards.

Sub menu

FluQuadri Inactivated Quadrivalent Influenza Vaccine (Split Virion), Influenza virus haemagglutinin 60mcg, 0.5mL suspension for injection (213963)

ARTG ID 213963

Related information

FluQuadri Inactivated Quadrivalent Influenza Vaccine (Split Virion), Influenza virus haemagglutinin 60 mcg, 0.5 mL suspension for injection, Sanofi Aventis Australia Pty Ltd, CON-262

FluQuadri Inactivated Quadrivalent Influenza Vaccine (Split Virion), Influenza virus haemagglutinin 60 mcg, 0.5 mL suspension for injection, Sanofi Aventis Australia Pty Ltd, CON-268

FluQuadri Inactivated Quadrivalent Influenza Vaccine (Split Virion), Influenza virus haemagglutinin 60 mcg, 0.5 mL suspension for injection, Sanofi Aventis Australia Pty Ltd, CON-274

FluQuadri Inactivated Quadrivalent Influenza Vaccine (Split Virion), Influenza virus haemagglutinin 60 mcg, 0.5 mL suspension for injection, Sanofi Aventis Australia Pty Ltd, CON-333

FluQuadri Inactivated Quadrivalent Influenza Vaccine (Split Virion), Influenza virus haemagglutinin 60 mcg, 0.5 mL suspension for injection, Sanofi Aventis Australia Pty Ltd, CON-334

FluQuadri Inactivated Quadrivalent Influenza Vaccine (Split Virion), Influenza virus haemagglutinin 60mcg, 0.5mL suspension for injection, Sanofi Aventis Australia Pty Ltd, CON-331

FluQuadri Inactivated Quadrivalent Influenza Vaccine (Split Virion), Influenza virus haemagglutinin 60mcg, 0.5mL suspension for injection, Sanofi Aventis Australia Pty Ltd, CON-408

Help us improve the Therapeutic Goods Administration site